Epilepsy Management in Tuberous Sclerosis Complex: Existing and Evolving Therapies and Future Considerations.

[1]  L. Lagae,et al.  Early epileptiform EEG activity in infants with tuberous sclerosis complex predicts epilepsy and neurodevelopmental outcomes , 2021, Epilepsia.

[2]  Mengyang Wang,et al.  Predictors and Long-term Outcome of Resective Epilepsy Surgery in Patients with Tuberous Sclerosis Complex: A Single-centre Retrospective Cohort Study , 2021, Seizure.

[3]  Emily A. Mirro,et al.  Brain‐Responsive Neurostimulation for the treatment of adults with epilepsy in tuberous sclerosis complex: A case series , 2021, Epilepsia open.

[4]  C. Marras,et al.  Surgery for drug-resistant tuberous sclerosis complex-associated epilepsy: who, when, and what. , 2021, Epileptic disorders : international epilepsy journal with videotape.

[5]  M. Likeman,et al.  The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial , 2021, EClinicalMedicine.

[6]  M. Fox,et al.  Tuber Locations Associated with Infantile Spasms Map to a Common Brain Network , 2021, Annals of neurology.

[7]  Mathieu Lemaire,et al.  The Phenotypic Spectrum of Tuberous Sclerosis Complex: A Canadian Cohort , 2021, Child neurology open.

[8]  A. Stemmer-Rachamimov,et al.  Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin , 2021, Science Advances.

[9]  E. Wirrell,et al.  Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex , 2020, JAMA neurology.

[10]  Ji Wang,et al.  Quality of life in children with tuberous sclerosis complex: A pediatric cohort study , 2020, CNS neuroscience & therapeutics.

[11]  L. Lagae,et al.  Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial , 2020, Annals of neurology.

[12]  S. Roberds,et al.  Approach to Preventive Epilepsy Treatment in Tuberous Sclerosis Complex and Current Clinical Practice in 23 Countries. , 2020, Pediatric neurology.

[13]  E. Widjaja,et al.  Vigabatrin-related adverse events for the treatment of epileptic spasms: systematic review and meta-analysis , 2020, Expert review of neurotherapeutics.

[14]  G. Mathern,et al.  Effect of Gene Mutation on Seizures in Surgery for Tuberous Sclerosis Complex , 2020, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[15]  G. Cutter,et al.  Epilepsy Risk Prediction Model for Patients With Tuberous Sclerosis Complex. , 2020, Pediatric neurology.

[16]  B. Porter,et al.  Caregivers’ impression of epilepsy surgery in patients with tuberous sclerosis complex , 2020, Epilepsy & Behavior.

[17]  H. Weiner,et al.  Epilepsy surgery in tuberous sclerosis complex (TSC): emerging techniques and redefinition of treatment goals , 2020, Child's Nervous System.

[18]  Hoon-Chul Kang,et al.  Long-term outcomes of ketogenic diet in patients with tuberous sclerosis complex-derived epilepsy , 2020, Epilepsy Research.

[19]  Yang-Yang Wang,et al.  Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: A prospective cohort study , 2020, Seizure.

[20]  J. Madsen,et al.  Pilot Study of Neurodevelopmental Impact of Early Epilepsy Surgery in Tuberous Sclerosis Complex. , 2020, Pediatric neurology.

[21]  A. Vignoli,et al.  Electro-clinical and neurodevelopmental outcome in six children with early diagnosis of tuberous sclerosis complex and role of the genetic background , 2020, Italian Journal of Pediatrics.

[22]  Zhang Hongying,et al.  Deep brain stimulation of anterior thalamic nucleus for the treatment of a patient with tuberous sclerosis-related refractory epilepsy. , 2020, World neurosurgery.

[23]  E. Thiele,et al.  Cannabidiol in treatment of refractory epileptic spasms: An open-label study , 2020, Epilepsy & Behavior.

[24]  I. Scheffer,et al.  Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome , 2020, JAMA neurology.

[25]  L. Lagae,et al.  Epilepsy and Neurodevelopmental Comorbidities in Tuberous Sclerosis Complex: A Natural History Study. , 2020, Pediatric neurology.

[26]  F. Rosenow,et al.  A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC) , 2020, Orphanet Journal of Rare Diseases.

[27]  Yi Yao,et al.  Resective epilepsy surgery in tuberous sclerosis complex: a nationwide multicentre retrospective study from China. , 2020, Brain : a journal of neurology.

[28]  P. Kahane,et al.  Epileptogenicity in tuberous sclerosis complex: A stereoelectroencephalographic study , 2019, Epilepsia.

[29]  D. Krueger,et al.  Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex. , 2019, Pediatric neurology.

[30]  K. Kotulska,et al.  Preventive Antiepileptic Treatment in Tuberous Sclerosis Complex: Long-Term, Prospective Trial. , 2019, Pediatric neurology.

[31]  N. Limdi,et al.  Scalp EEG spikes predict impending epilepsy in TSC infants: A longitudinal observational study , 2019, Epilepsia.

[32]  M. Neary,et al.  Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex , 2019, Epilepsia open.

[33]  T. Okanishi,et al.  Corpus callosotomy for drug-resistant spasms associated with tuberous sclerosis complex , 2019, Epilepsy & Behavior.

[34]  D. Franz,et al.  Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures , 2019, Expert review of neurotherapeutics.

[35]  A. Lyon,et al.  Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy: Preliminary Results of the CARE-E Study , 2019, Front. Neurol..

[36]  M. Neary,et al.  Health utilities and quality of life in individuals with tuberous sclerosis complex (TSC) who experience epileptic seizures: A web-based survey , 2019, Epilepsy & Behavior.

[37]  M. Jaatun,et al.  Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study , 2018, Epilepsia open.

[38]  B. McCoy,et al.  A Review of Investigations for Patients With Tuberous Sclerosis Complex Who Were Referred to the Tuberous Sclerosis Clinic at The Hospital for Sick Children: Identifying Gaps in Surveillance. , 2019, Pediatric neurology.

[39]  D. Friedman,et al.  Invasive monitoring after resection of epileptogenic neocortical lesions in multistaged epilepsy surgery in children , 2018, Epilepsy Research.

[40]  Shaun A. Hussain,et al.  High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex , 2018, Epilepsy Research.

[41]  O. Devinsky,et al.  Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. , 2018, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[42]  J. French,et al.  Everolimus for treatment-refractory seizures in TSC , 2018, Neurology. Clinical practice.

[43]  D. Krueger,et al.  mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex , 2018, American journal of medical genetics. Part C, Seminars in medical genetics.

[44]  L. Lagae,et al.  Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations. , 2018, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[45]  D. Pearson,et al.  A clinical update on tuberous sclerosis complex‐associated neuropsychiatric disorders (TAND) , 2018, American journal of medical genetics. Part C, Seminars in medical genetics.

[46]  A. Dressler,et al.  Everolimus in infants with tuberous sclerosis complex–related West syndrome: First results from a single‐center prospective observational study , 2018, Epilepsia.

[47]  O. Snead,et al.  A prospective open‐label trial of a CBD/THC cannabis oil in dravet syndrome , 2018, Annals of clinical and translational neurology.

[48]  Anup D. Patel,et al.  Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome , 2018, The New England journal of medicine.

[49]  J. French,et al.  Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures , 2018, Epilepsia.

[50]  M. Sahin,et al.  Vigabatrin for Epileptic Spasms and Tonic Seizures in Tuberous Sclerosis Complex , 2018, Journal of child neurology.

[51]  Anup D. Patel,et al.  Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome , 2018, Neurology.

[52]  Eric Marsh,et al.  Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial , 2018, The Lancet.

[53]  B. McCoy,et al.  The Utility of Surveillance Electroencephalography to Guide Early Antiepileptic Drug Therapy in Infants With Tuberous Sclerosis Complex. , 2017, Pediatric neurology.

[54]  Hoon-Chul Kang,et al.  Ketogenic Diet for the Management of Epilepsy Associated with Tuberous Sclerosis Complex in Children , 2017, Journal of epilepsy research.

[55]  I. Scheffer,et al.  Trial of Cannabidiol for Drug‐Resistant Seizures in the Dravet Syndrome , 2017, The New England journal of medicine.

[56]  A. Byars,et al.  Influence of seizures on early development in tuberous sclerosis complex , 2017, Epilepsy & Behavior.

[57]  A. Wilfong,et al.  Long-term treatment of epilepsy with everolimus in tuberous sclerosis , 2016, Neurology.

[58]  G. Kasprian,et al.  Efficacy and safety of Everolimus in children with TSC - associated epilepsy – Pilot data from an open single-center prospective study , 2016, Orphanet Journal of Rare Diseases.

[59]  J. French,et al.  Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study , 2016, The Lancet.

[60]  Simon J. Vogrin,et al.  Centre of epileptogenic tubers generate and propagate seizures in tuberous sclerosis. , 2016, Brain : a journal of neurology.

[61]  E. Thiele,et al.  Cannabidiol as a new treatment for drug‐resistant epilepsy in tuberous sclerosis complex , 2016, Epilepsia.

[62]  G. Mathern,et al.  Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with Tuberous Sclerosis Complex , 2016, Epilepsy & Behavior.

[63]  D. Rizopoulos,et al.  Sirolimus for epilepsy in children with tuberous sclerosis complex , 2016, Neurology.

[64]  K. Polański,et al.  Long-term High Fat Ketogenic Diet Promotes Renal Tumor Growth in a Rat Model of Tuberous Sclerosis , 2016, Scientific Reports.

[65]  G. Cutter,et al.  Clinical Electroencephalographic Biomarker for Impending Epilepsy in Asymptomatic Tuberous Sclerosis Complex Infants. , 2016, Pediatric neurology.

[66]  Ling Lin,et al.  Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing , 2015, PLoS genetics.

[67]  J. González-Martínez,et al.  Resective Epilepsy Surgery for Tuberous Sclerosis in Children: Determining Predictors of Seizure Outcomes in a Multicenter Retrospective Cohort Study. , 2015, Neurosurgery.

[68]  Y. Vergouwe,et al.  Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs , 2015, Epilepsia.

[69]  P. J. Vries,et al.  Neurological and neuropsychiatric aspects of tuberous sclerosis complex , 2015, The Lancet Neurology.

[70]  P. Curatolo.  Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. , 2015, Pediatric neurology.

[71]  Jeffrey R. Tenney,et al.  Long-term outcomes of resective epilepsy surgery after invasive presurgical evaluation in children with tuberous sclerosis complex and bilateral multiple lesions. , 2015, Journal of neurosurgery. Pediatrics.

[72]  B. King,et al.  Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist. , 2015, Pediatric neurology.

[73]  K. Kotulska,et al.  EEG abnormalities preceding the epilepsy onset in tuberous sclerosis complex patients - a prospective study of 5 patients. , 2014, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[74]  M. Duchowny,et al.  Predictors of seizure‐free outcome after epilepsy surgery for pediatric tuberous sclerosis complex , 2013, Epilepsia.

[75]  A. Wilfong,et al.  Treating Epilepsy in Tuberous Sclerosis with Everolimus: Getting Closer , 2014, Epilepsy currents.

[76]  Hope Northrup,et al.  Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. , 2013, Pediatric neurology.

[77]  D. Krueger,et al.  Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference , 2013, Pediatric neurology.

[78]  Jian-Guo Zhang,et al.  Predictors of seizure freedom after surgical management of tuberous sclerosis complex: A systematic review and meta-analysis , 2013, Epilepsy Research.

[79]  G. Guyatt,et al.  Predictors of Seizure Outcomes in Children with Tuberous Sclerosis Complex and Intractable Epilepsy Undergoing Resective Epilepsy Surgery: An Individual Participant Data Meta-Analysis , 2013, PloS one.

[80]  E. Thiele,et al.  Low glycemic index treatment for epilepsy in tuberous sclerosis complex , 2012, Epilepsy Research.

[81]  K. Kotulska,et al.  Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. , 2011, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[82]  Kelvin A. Yamada,et al.  The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway , 2011, Epilepsia.

[83]  P. Curatolo,et al.  Vagus nerve stimulation for refractory epilepsy in tuberous sclerosis. , 2010, Pediatric neurology.

[84]  E. Thiele,et al.  Tumor growth in patients with tuberous sclerosis complex on the ketogenic diet , 2010, Brain and Development.

[85]  S. Nagarajan,et al.  Noninvasive testing, early surgery, and seizure freedom in tuberous sclerosis complex , 2010, Neurology.

[86]  S. Camposano,et al.  The natural history of epilepsy in tuberous sclerosis complex , 2009, Epilepsia.

[87]  O. Devinsky,et al.  Refractory epilepsy in tuberous sclerosis: Vagus nerve stimulation with or without subsequent resective surgery , 2009, Epilepsy & Behavior.

[88]  S. Jóźwiak,et al.  Tuberous sclerosis , 2008, The Lancet.

[89]  E. Thiele,et al.  Vagus nerve stimulation for intractable epilepsy in tuberous sclerosis complex , 2008, Epilepsy & Behavior.

[90]  N. Zamponi,et al.  Vagus nerve stimulation (VNS) is effective in treating catastrophic 1 epilepsy in very young children , 2008, Neurosurgical Review.

[91]  P. Crino,et al.  The tuberous sclerosis complex. , 2006, The New England journal of medicine.

[92]  G. Coppola,et al.  The effects of the ketogenic diet in refractory partial seizures with reference to tuberous sclerosis. , 2006, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[93]  E. Kossoff,et al.  Tuberous Sclerosis Complex and the Ketogenic Diet , 2005, Epilepsia.

[94]  D. Parain,et al.  Vagal nerve stimulation in tuberous sclerosis complex patients. , 2001, Pediatric neurology.

[95]  R. Schwartz,et al.  Usefulness of Diagnostic Criteria of Tuberous Sclerosis Complex in Pediatric Patients , 2000, Journal of child neurology.

[96]  Christopher N Martyn,et al.  Prevalence of tuberous sclerosis estimated by capture-recapture analysis , 1998, The Lancet.